Multicenter open non-comparative clinical study to evaluate the efficacy and safety of three months Tavanic course (levofloxacin) in combine treatment of multi-drug-resistant tuberculosis (MDR-TB).
Phase of Trial: Phase IV
Latest Information Update: 03 Mar 2012
At a glance
- Drugs Levofloxacin (Primary) ; Antituberculars
- Indications Pulmonary tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 03 Jun 2008 Status changed from recruiting to completed according to ClinicalTrials.gov
- 07 Aug 2007 New trial record.